Dyne Therapeutics

Dyne Therapeutics, founded in 2018, is the first biopharmaceutical company to develop targeted therapeutic drugs for patients with severe muscle diseases. Under the leadership of a professional clinical medical team, Dyne Therapeutics is developing FORCE™ technology, which combines antibodies and drugs to accurately deliver medication to diseased cells, providing treatment to affected areas. Dyne Therapeutics has an extensive product pipeline for treating serious muscle diseases, including clinical programs for treating Myotonic Dystrophy Type 1 (DM1) and Duchenne Muscular Dystrophy (DMD), as well as a preclinical program for treating Facioscapulohumeral Muscular Dystrophy (FSHD).